fda and semaglutide ban on compounding news alerts health care providers, compounders patients of dosing errors associated with compounded injectable products The FDA's Decision to – FDA approves obesity drug that – FDA Warns on Certain Forms

Acknowledgements This work was supported by National Research Foundation grants [2021R1A5A2021614, 2021R1A2C1005513, and 2022M3A9G8095334] funded by the Ministry of Science and ICT of Korea

But it wasnt until semaglutide hit the market (first as Ozempic [archived link] in 2017 followed by Wegovy [archived link]) in 2021) that GLP-1 RAs captured the worlds attention

Consult a healthcare professional if using for more than 8 weeks

The bottom line Similar to the treatments for other chronic conditions, medications to manage obesity are designed to be taken long-term, even after you reach your weight-loss goal

Flow Wellness often recommends allowing the medication to sit at room temperature briefly before injection, if consistent with pharmacy instructions

It is commonly used to contour the lower abdomen, upper stomach, and flanks (love handles), providing a more sculpted appearance